For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Return to shareholders -- $1.4 billion was returned to shareholders as of fiscal Q3 2025 through dividends and share repurchases. Anticipated step-up in expenses -- Research and development, as well ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

Obsidian mines mined by the pre-Hispanic Mesoamerican tribes of Central Mexico, located just 31 miles (49.88 kilometers) northeast of the ancient city of Teotihuacan, were discovered by archaeologists ...

NEW YORK, Oct 15 (Reuters) - Optimism over the profit potential of artificial intelligence has helped drive the U.S. stock market to record highs, but investors are looking for weak spots that could ...

The S&P 500 (SNPINDEX: ^GSPC) market index is pretty broad. It tracks the performance of roughly 500 stocks, hand-picked by an expert panel to reflect the large-cap portion of the American stock ...

Elizabeth M. Stone ([email protected]), Rutgers University, New Brunswick, New Jersey. Nicholas J. Seewald, University of Pennsylvania, Philadelphia, Pennsylvania ...

aCentre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa ...

Introduction: The World Health Organization (WHO) recently updated its guidelines for HIV post-exposure prophylaxis (PEP). These guidelines recommend community delivery and task-sharing for PEP ...